✦ LIBER ✦

535 - Topotecan: A “compassionate use” study in patients with advanced epithelial ovarian cancer refractory to other therapies

✍ Scribed by T. Bauknecht; H.-J. Lueck; H. Calvert; R. Kreienberg; R. Pastovic

Book ID: 117664783
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 261 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85049-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Intravenous DX-8951f i

Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan

✍ C. F. VERSCHRAEGEN; C. LEVENBACK; M. VINCENT; J. WOLF; M. BEVERS; E. LOYER; A. P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Phase 1b-2a study to reverse platinum re

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

✍ Siqing Fu; Wei Hu; Revathy Iyer; John J. Kavanagh; Robert L. Coleman; Charles F. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 298 KB 👁 1 views

A Phase II Study of the MDR Inhibitor Bi

A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

✍ Michael V. Seiden; Kenneth D. Swenerton; Ursula Matulonis; Susan Campos; Peter R 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Gefitinib in combination with tamoxifen

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

✍ Uwe Wagner; Andreas du Bois; Jacobus Pfisterer; Jens Huober; Sybille Loibl; Hans 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Nadir CA125 and second look surgery in p

Nadir CA125 and second look surgery in patients with advanced stage epithelial ovarian cancer treated with intravenous compared to intraperitoneal chemotherapy: A study of Gynecologic Oncology Group Protocols 114 and 172

✍ S. Richard; A. Miller; M. Markman; D. Armstrong; J. Walker; T. Krivak 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 128 KB

A phase III randomized trial of BAY 12-9

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

✍ H. Hirte; I.B. Vergote; J.R. Jeffrey; R.N. Grimshaw; S. Coppieters; B. Schwartz; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB